Immunovant posts $0.73/sh Q4 loss; IMVT-1402 hits 72.7% ACR20 in D2T RA at Week 16

Immunovant, Inc.

IMVT-1402 in D2T RA: 72.7% ACR20, 54.5% ACR50, 35.8% ACR70 at Week 16; open-label, blinded assessors; safety well-tolerated.
Cash $902.1M as of Mar 31, 2026; provides runway to potential launch of IMVT-1402 in GD.
Net loss Q4 FY2026 $147.9M ($0.73/share) vs $106.4M ($0.64/share) YoY; FY net loss $505.6M ($2.77/share).
Batoclimab discontinued after Phase 3 TED miss; $39M contract cost recognized in Q4.
CLE proof-of-concept fully enrolled; topline data expected H2 2026. Other trials on track for GD, MG, CIDP, SjD.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunovant, Inc. reported fourth quarter and fiscal year ended March 31, 2026 results: net income $147.9 million ($0.73 per common share), EPS ($0.73 per common share).

Period: fourth quarter and fiscal year ended March 31, 2026
Net income: $147.9 million ($0.73 per common share)
EPS: ($0.73 per common share)
Result: reported results

Exact text from the filing

Net loss was $147.9 million ($0.73 per common share) for the three months ended March 31, 2026, compared to $106.4 million ($0.64 per common share) for the three months ended March 31, 2025.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunovant, Inc. filing history →

Source: SEC EDGAR

accession 0001764013-26-000062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.